Nextbiomedical넥스트바이오메디컬
389650 · KOSDAQ · ₩389650 · 넥스트바이오메디컬
₩29,300▲ ₩1,300 (4.64%)End-of-day · Oct 28, 2026 · End-of-day prices.
Margins
| TTM | 2025 | 2024 | |
|---|---|---|---|
| Gross margin | 70.5% | 70.0% | 61.0% |
| Operating margin | −12.9% | −4.4% | −37.5% |
| Net margin | −0.2% | −1.9% | 30.0% |
Growth (year on year)
| TTM | 2025 | 2024 | |
|---|---|---|---|
| Revenue growth | +8.0% | +72.7% | — |
| Operating income growth | −219.3% | +79.9% | — |
| Net income growth | +86.4% | −110.9% | — |
Returns
| TTM | 2025 | 2024 | |
|---|---|---|---|
| Return on equity | −0.1% | −0.7% | 6.3% |
| Return on assets | −0.1% | −0.5% | 4.9% |
Leverage and liquidity
| TTM | 2025 | 2024 | |
|---|---|---|---|
| Liabilities to equity | 29.3% | 23.2% | 30.2% |
| Net debt to equity | −33.3% | −31.5% | −55.2% |
| Current ratio | 501.6% | 537.9% | 394.5% |
Calculated from filed financial statements. TTM = trailing 12 months.
Also known as: Nextbiomedical / 넥스트바이오메디컬 / 389650 / KRX:389650
Source: KRX statistical information